|Cancer Therapeutics & Partnering Summit|
Oncology Partnering & Deal-Making
Complementary & Companion Diagnostics in Oncology
Cancer Diagnostics have become fully ingrained in modern cancer treatment programs, and will continue to have an expanding role. Liquid biopsy approaches could exceed imaging in both sensitivity and specificity and yield more information on the tumor. The need for diagnostics for guiding immunotherapy is clear. Precision drug treatment and personal vaccines require a high resolution diagnostic of each tumor.
Technological advances have provided new levels of sensitivity that allow biomarker evaluation in the circulation, expanding the diversity of biomarker targets and facilitating time-based monitoring. In addition, information from the growing array of approaches has identified relevant molecules for targeted drug design. Together, these have facilitated a more intelligent approach to the development of therapy and its delivery to the cancer patient.
We invite you to attend the 3rd Complementary & Companion Diagnostics Conference, which will take place September 28-29, 2017 in San Diego, CA. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and discuss new research in cancer diagnostics, including next generation sequencing, the use of clinical utility of cell-free DNA liquid biopsy, patient selection for cancer drug development, and correlative predictive markers.
We hope to see you there!
The 2017 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
ACEA Biosciences, Inc. is a pioneer in the development and commercialization of highperformance microelectronic systems for cell-based assays. ACEA’s xCELLigence® systems are widely used in academic labs, government institutions, biotech and pharma companies around the world to study cell adhesion, cell migration/invasion, GPCR/RTK signaling, cell proliferation and compound/cell/viral-mediated cytotoxicity.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC’s radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.